Lanier Biotherapeutics Announces Issuance of U.S. Patent for IL-25 Binding Molecules
November 14, 2022 13:00 ET
|
Lanier Biotherapeutics
BOGART, Georgia, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lanier Biotherapeutics Inc., (“Lanier” or the “Company”), a developer of first-in-class antibodies targeting retina, dermatology, Type 2...
Lanier Biotherapeutics to Present Seminal LNR125 Publication at American Thoracic Society Meeting
May 13, 2022 10:30 ET
|
Lanier Biotherapeutics
BOGART, Ga., May 13, 2022 (GLOBE NEWSWIRE) -- Lanier Biotherapeutics Inc., (“Lanier” or the “Company”), a developer of first-in-class antibodies targeting retina, dermatology, and Type 2...
Newly Formed Lanier Biotherapeutics Enters into License Agreement with Alloy Therapeutics
October 05, 2021 08:00 ET
|
Lanier Biotherapeutics
BOGART, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Lanier Biotherapeutics Inc., (“Lanier” or the “Company”), a developer of first-in-class antibodies targeting retina, dermatology, and Type 2...